ALB and triple-negative breast carcinoma: Fatma Yurt and colleagues demonstrated that albumin-based nanoplatforms serve as exceptional drug delivery systems for chemotherapeutic agents targeting triple-negative breast cancer (TNBC) through their innovative development of docetaxel-loaded durvalumab-targeted human serum albumin nanoparticles.